What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? 

Anthony F. Shields, MD, PhD

  H&O  Which patients with colon cancer require adjuvant therapy? AS  Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

Direct-to-Consumer Advertising of Cancer Treatments

Lowell E. Schnipper, MD

  H&O  What have studies shown about direct-to-consumer advertising of medical treatments? LS  A few studies have evaluated direct-to-consumer advertising of medical treatments, but they are […]

How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver

Mark A. Socinski, MD

Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]

Current Challenges in the Management of Essential Thrombocythemia

Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD

  Abstract: Essential thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms, a category that also includes polycythemia vera and primary myelofibrosis. […]

Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer

Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD

  Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]

View More Issues